| Literature DB >> 32971033 |
Pavithra Natarajan1, John M Tomich2.
Abstract
Bionanotechnology has developed rapidly over the past two decades, owing to the extensive and versatile, functionalities and applicability of nanoparticles (NPs). Fifty-one nanomedicines have been approved by FDA since 1995, out of the many NPs based formulations developed to date. The general conformation of NPs consists of a core with ligands coating their surface, that stabilizes them and provides them with added functionalities. The physicochemical properties, especially the surface composition of NPs influence their bio-interactions to a large extent. This review discusses recent studies that help understand the nano-bio interactions of iron oxide and gold NPs with different surface compositions. We discuss the influence of the experimental factors on the outcome of the studies and, thus, the importance of standardization in the field of nanotechnology. Recent studies suggest that with careful selection of experimental parameters, it is possible to improve the positive correlation between in vitro and in vivo studies. This provides a fundamental understanding of the NPs which helps in assessing their potential toxic side effects and may aid in manipulating them further to improve their biocompatibility and biosafety.Entities:
Keywords: Biological interactions; Experimental factors; Gold; Iron oxide; Nanoparticles; Standardization
Mesh:
Substances:
Year: 2020 PMID: 32971033 PMCID: PMC7503072 DOI: 10.1016/j.abb.2020.108592
Source DB: PubMed Journal: Arch Biochem Biophys ISSN: 0003-9861 Impact factor: 4.013
Fig. 1Nanoparticle (NP) - bioconjugates: (A) A nano-bioconjugate can be composed of varied components of fundamentally different origin. This figure presents these components and their configurations: (i) Biomolecule interacting with NP core, (ii) biomolecule interacting with a NP core via intermediate ligands, (iii) biomolecule interacting with NP shell layer that surrounds the NP core, (iv) biomolecule interacting with NP shell layer/NP core via intermediate ligands, (v) porous NP core containing entrapped biomolecules, (vi) porous or hollow NP core containing entrapped biomolecules surrounded by a NP shell layer, (vii) NP core (or NP core/NP shell structures) particles smaller in size than the much larger biomolecule, (viii) NP core (or NP core/NP shell structures) particles smaller in size than the much larger biomolecule attached via intermediate ligands. (B) A representative NP decorated with multiple functional molecules (e.g., nucleic acids, proteins, drugs, peptides). NPs have great potential since they can provide multiple functions in one active platform. (C) The four general schemes routinely used for the conjugation of peptides to NP materials. These schemes are also representative of the type of interactions involved in the binding of biomolecules in general to NPs. (D) Distribution of types of nanoparticles in clinical trials, explored for use as nanomedicines. Data was obtained in April 2020, from using the search term ‘nanoparticles’. This distribution is representative of active clinical trial studies using nanoparticles as drug delivery systems or imaging agents. Inorganic/metallic NPs in trial have been further categorized based upon their composition.
Adapted with permission from Sapsford, K. E et al. [1] Analyzing nanomaterial bioconjugates: a review of current and emerging purification and characterization techniques. Anal Chem 2011, 83 (12), 4453–88. Copyright (2020) American Chemical Society. Permission for part of the figure obtained from IOP publishing, Aubin-Tam et al. [16]. Structure and function of nanoparticle-protein conjugates. Biomedical Materials, 3 (3). © IOP Publishing. Reproduced with permission. All rights reserved.
Applications of nanoparticles with different biocompatible surface ligands.
| Category of functionalizing molecules | Nanoparticles & Functionalizing molecules | Applications | References |
|---|---|---|---|
| Polymers & carbohydrates | FeONPs + PEG variations (NHS-PEG-SH, PEG-SH) | Magnet guided delivery, MRI, Probes for cancer imaging | Lee [ |
| AuNPs + 2-deoxyglucose | Theranostics | Suvarna [ | |
| Lipids & Liposomes | AuNPs + Soybean lecithin, cholesterol liposome | Photothermal treatment | Xing [ |
| AgNPs/AuNPs + POPC, POPG, Cholesterol lipid bilayer | SERS probe | Bhowmik [ | |
| AuNPs + DC-Chol, DOPE, Chol | siRNA delivery | Kong [ | |
| FeONPs + OQLCS polymeric liposomes | MRI | Liao [ | |
| Peptides | FeONPs + TAT CPP | ROS induced radiation, Dox-delivery | Hauser [ |
| FeONPs + H625-CPP | MRI, Far red imaging, hyperthermia, drug delivery | Perillo [ | |
| AuNPs + Penetratin peptide | Photothermal, NIR | Yin [ | |
| AuNPs, FeONPs + BAPs | CT, confocal imaging, probes for molecular interactions, cell sorting and quantification | Natarajan [ | |
| Proteins & Antibodies | AuNPs + albumin variants (BSA, albumin, Nab-paclitaxel) | photothermal chemotherapy, anticancer drug delivery | Nosrati [ |
| FeONPs + Anti-Her 2, ScFvEGFR | Targeted MRI | Chen [ | |
| Nucleic acids | PEI-siRNA | siRNA delivery | Wang [ |
| AuNPs + Aptamers | LSPR mediated colorimetric detection | Lia [ | |
| FeONPs + Aptamers | Detection of biological molecules | Fernandez [ |
POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPG, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol; DOPE, Dioleoylphosphatidylethanolamine; OQLCS, octadecyl-quaternized lysine modified chitosan; TAT, Transactivator of transcription; CPP, Cell penetrating peptide; ScFvEGFR, short chain variable, anti-EFGR.
Summary of studies on effects of NPs in vitro ‘and’ in vivo.
| NPs | Surface coating | Cells | Animal model & strain | Route of administration | Conclusion | Ref |
|---|---|---|---|---|---|---|
| AuNPs | Citrate | HepG2 HT29 | Wistar rats | Intraperitoneal (i.p.) | No effect was observed on cytokines secretion & other serum contents in vivo but damage to genetic material by smaller NPs, observed in vitro. | Lopez-Chaves [ |
| IONPs | PEI & PEG | RAW264.7 SKOV-3 | BALB/c | Intravenous (i.v.) | PEI-IONPs ≫ toxic to cells in vitro & ↑↑ toxicity in vivo causing death of mice at specific dosage Size & surface functionalization have a huge impact on the cellular uptake, toxicity, tissue distribution & clearance in vivo | Feng [ |
| AuNPs & Nanorods | Polyallylamine hydrochloride (PAH) | C3H fibroblasts HTC | Wistar rats | Oral | Some adverse effect on liver cells in vitro & oxidative stress and inflammation in vivo. No major adverse effects observed in vivo | Bernardi [ |
| AuNPs | PEG | RAW264.7 | Swiss mice | i.v. | Dramatically lower uptake of NPs in vitro but fast clearance of NPs in vivo. No correlation between in vitro and in vivo data | Zhang [ |
Fig. 2Experimental factors impacting in vitro studies –(a) Cell culture medium determines the biocorona formation around NPs. (b) Dosage, exposure type and (c) time should be chosen based on intended applications and potential exposure levels. (d) Cell culture methods, cell types and cell origin are the other factors that must be carefully selected to accurately determine the net effect of NPs.
Effect of nanoparticles on cellular toxicity and viability.
| NP | Surface coating | Cell line | Media | Dosage | Time of exposure | Changes observed leading to cellular toxicity | Reference |
|---|---|---|---|---|---|---|---|
| 6 nm SPIONs | Citrate | HL60 in suspension | RPMI | 0–150 μg/mL | 24 h | Cells in 2D culture less affected than cells in 3D ↑ Surface area of exposure = ↑ toxicity | Milla et al. [ |
| MDA-MB231 (2D) | |||||||
| MDA-MB231 (3D) | |||||||
| bEND 3 | |||||||
| 15 nm, 40 nm, 80 nm AuNPs | Citrate | Hela | DMEM & RPMI | 1 pM - 1 nM | 48 h & 96 h | Viability of HeLa cells ↓than U937 AuNPs in RPMI more toxic to cells than AuNPs in DMEM | Maiorano et al. [ |
| U937 | |||||||
| 10 nm AuNPs | citrate | HUVECs | DMEM | 0–64 μg/mL | 24 h | ↓ cell viability at 5% serum in comparison to 10% serum ↑ uptake in low serum media | Gunduz et al. [ |
| AuNPs | Nanospheres with Citrate & PAA | Human dermal fibroblasts | DMEM | 0.1 nM Acute vs chronic exposure | 24 h (Acute) | AuNPs were generally non-toxic Uptake: PAA rods > PAA spheres > citrate spheres ~ PEG rods Gene expression changes observed ↑ in nonchronic exposure Cells developed adaptive response to chronic exposure EG rods ↑ gene expression changes | Falagan-Lotsch et al. [ |
| ~4 nm AuNPs | polymer PMA | hNSC | DMEM | 0–150 nM | 24 h | AuNPs were more toxic than FeONPs to all cells Primary stem cells more susceptible to FeONPs induced toxicity Human cells morphology was affected more than mouse cells in general | Joris et al. [ |
| 10 nm SPIONs | Proprietary ligands | Primary Rat hepatocytes | DMEM | 0–400 μg/mL | 24 h & 48 h | Cell viability ↓ with ↑ concentrations in single dose vs cumulative treatment Cumulative dosage more deleterious to hepatocyte functioning and metabolic competency ll treatments induced ROS production | Gokduman et al. [ |
| One high dose vs cumulative dose | |||||||
| 10 nm & 30 nm FeONPs | PEG & PEI | RAW 264.7 | DMEM | 0–400 μg/mL | 1, 2, 4, 16 h | PEI FeONPs more toxic than PEG FeONPs PEI FeONPS ↑ ROS, Apoptosis PEG FeONPs induced autophagy | Feng et al. [ |
| 60 nm FEONPS | Naked | Rat Primary lymphocytes | RPMI | 0–800 μg/mL | 24 h | ↓ cell viability, ↑ ROS, ↑ Genotoxicity | Ansari et al. [ |
| ~16 nm FeONPs | DHCA | Human Bone derived mesenchymal stem cells | MEM | 0-1000 Fe μg/mL | 1, 4, 24 h | Moderate effect on cell viability ↑ ROS | Hachani at al [ |
Endocytosis of nanoparticles.
| NP | Surface coating | Cells | Inhibition mediated by | Uptake route | Reference |
|---|---|---|---|---|---|
| AuNPs | Glucose | A431 | Chemical inhibitors | GLUT-1 transporter mediated, CME & CvME | Dreifuss et al. [ |
| A549 | |||||
| PC3 | |||||
| B16F10 | |||||
| LNCaP | Lower uptake in GLUT-1 low cell lines via diffusion | ||||
| 3T3 | |||||
| AuNPs | PEG-SH - Cell penetrating peptides (CPP) | A549 | Chemical inhibitors | CME & Macropinocytosis | He et al. [ |
| B16F10 | |||||
| AuNPs | PEI-PEG + pDNA | HeLa | Chemical inhibitors | CME | Li et al. [ |
| AuNPs | His-PIMA-PEG-OCH3/NH2 + SVS-1 antimicrobial peptide | HeLa | Temperature | Energy independent, non-endocytic route | Kapur et al. [ |
| CHO | |||||
| FeONPs | Siloxane with free –COO groups | Primary human lung cells | Chemical inhibitors & Temperature | CvME | Sun et al. [ |
| b.End | |||||
| MDCK | |||||
| SPIONs | silane/silica with free –COO groups | HeLa | siRNA silencing | CvME & CDC42 mediated fluid phase endocytosis | Bohmer et al. [ |
| PEG | |||||
| SPIONs | PEG + Folic Acid + Fluorophores | HeLa | Chemical inhibitors | CME | Vannier et al. [ |
| MCF-7 | |||||
| MDA-MB435 | CME & ↓ CvME | ||||
| SPIONs | Sienna + (Trademarked) | A549 | siRNA silencing | CvME & Macropinocytosis | Guggenheim et al. [ |
| MDA | |||||
| HeLa | |||||
| THP-1 | CME, Macropinocytosis & Phagocytosis | ||||
| AuNPs | citrate | HUVECs | Chemical inhibitors | Macropinocytosis | Gunduz et al. [ |
| SPIONs | Branched amphiphilic peptide bilayer coated magnetic nanobeads (BAPc-MNBs) | IEC-18 | Chemical inhibitors | CvME, CME, Macropinocytosis (1 h) | Natarajan et al. [ |
Fig. 4Bio-interactions of nanoparticles – Nanoparticles can be administered via different routes (i) which shapes their tissue distribution (ii). The cellular interactions of the NPs ultimately affect their fate in vivo. The physicochemical properties of the NPs impact the uptake mechanism (iii) which consecutively determines their intracellular fate. The NPs are sorted into different compartments based on the endocytic route. The NPs can affect the gene expression by directly interacting with the DNA or indirectly due the reactive oxygen species (ROS) generated. This may also lead to metabolic changes. Reactive nitrate species (RNS) produced mainly by immune cells such as macrophages and neutrophils along with the ROS are considered to be indicators of cellular activation. Altogether, the intracellular changes may cause cellular toxicity (iv) and cause an immune response by inducing changes in cytokine and chemokines secretion (v). NPs can also be exocytosed in vesicles called exosomes which may be inherently targeted to different tissues. Therefore, a cascade of events determines the bioavailability, clearance, toxicity profile and thus, the net effect of NPs.
CCV-Clathrin coated vesicles; CCIV- Clathrin caveolin independent vesicles.
Immunogenicity of nanoparticles.
| NP | Surface coating | Cells/Cell line | Changes in secreted cytokines, chemokines & iNOS | Type of overall response | References |
|---|---|---|---|---|---|
| FeONPs | Polygluocse sorbitol carboxymethyl ether | RAW 264.7 | TNF- α ↑, IL-10 ↓, iNOS↑ | Pro-inflammatory, M1 macrophages polarization | Zanganeh et al. [ |
| FeONPs | Ovalbumin | RAW 264.7 | TNF- ↑, IL-6↑, IFN-γ ↑ | Pro-inflammatory, NPs behave as adjuvants | Zhao et al. [ |
| DC2.4 | |||||
| SPIONs | PEI- stabilized with: Zonyl-FSA Surfactant Pluronic-F127 surfactant | SVEC | TNF-α ↑, IL-6↑, IL-23 ↑, CCL1 ↑, CCL4 ↑, CCL5 ↑, TGF-β ↓, iNOS↑ | Pro-inflammatory, reduced cell migration | Mulens-Arias et al. [ |
| HUVECs | CCL2 ↑, CCL5↑, CXCL12↑, IL-23 A & TNF-α levels unchanged, slight ↑ TGF-β1 & VEGFA | Pro-inflammatory, reduced angiogenesis | |||
| THP-1 | IL-1β ↑, Il-6 ↑, TNF-α ↑, CCL2 ↑, IL-12↓ | Pro-inflammatory & altered M2 macrophages function | |||
| AuNPs | Hydrophilic zwitterionic polymer (ZDiMe) | J774.2 & RAW 264.7 | TNF-α unchanged | Neutral response | Moyano et al. [ |
| Hydrophobic zwitterionic polymer (ZDiPen) | TNF-α ↓ | Anti-inflammatory | |||
| Tetraethylene glycol modified | TNF-α ↓ | Anti-inflammatory |
Fig. 3Localization of NPs in tissues and the physiological barriers to their uptake – Biodistribution of NPs in organs/tissues is influenced by their ability to cross the various physiological barriers. Sequestration by macrophages of the mononuclear phagocytic system (MPS) causes faster clearance of NPs from circulation and they accumulate mainly in organs such as liver and spleen. Histopathological & electron microscopy analyses provide information on the localization of NPs within tissues i.e. accumulation of NPs in specific cells, extracellular or in interstitial spaces as well as sub-cellular localization, morphological changes and damage to tissues and cells. H & E staining of NPs treated - (a) Liver showing FeONPs localized in Kupffer cells, (b) Spleen with increased macrophages in the red-pulp area, (c) Kidneys showing slight degeneration of tubular epithelial cells cytoplasm, (d) and (e) Lungs with NPs localized in the alveolar epithelium and interstitial spaces, respectively. Electron micrographs show accumulation of NPs in the (A) cytoplasm of Kupffer cells and (B) lipid droplets of the hepatocytes.
Adapted and reprinted (a), (b), (c) from Nanomedicine-Nanotechnology Biology and Medicine.12 (6), Sabareeswaran, A.; Ansar, E.; Varma, P.; Mohanan, P.; Kumary, T., Effect of surface-modified superparamagnetic iron oxide nanoparticles (SPIONS) on mast cell infiltration: An acute in vivo study, with permission from Elsevier. © (2016) (d), (e) Scientific Reports, Sharma, A.; Cornejo, C.; Mihalic, J.; Geyh, A.; Bordelon, D.; Korangath, P.; Westphal, F.; Gruettner, C.; Ivkov, R., Physical characterization and in vivo organ distribution of coated iron oxide nanoparticles. © (2018) Springer Nature. (A) & (B) . Nanomedicine-Nanotechnology Biology and Medicine, 14 (1), Lopez-Chaves, C.; Soto-Alvaredo, J.; Montes-Bayon, M.; Bettmer, J.; Llopis, J.; Sanchez-Gonzalez, C., Gold nanoparticles: Distribution, bioaccumulation and toxicity. In vitro and in vivo studies, with permission from Elsevier. © (2018).
Biodistribution, systemic toxicity and immune response to nanoparticles in vivo.
| NPs | Surface coating | Animal model & strain | Route | Biodistribution | Toxicity and/or immune response | Ref | |
|---|---|---|---|---|---|---|---|
| Biochemical | Histopathological changes | ||||||
| FeONPs | PEG & PEI | BALB/c | i.v. | Liver, spleen > lungs, heart, kidney | ALT↑ (PEG), LDH ↑ (PEI) | ↑ macrophages in hepatic portal area | Feng [ |
| FeONPs | PEG-PEI, Carboxymethyl -dextran | Nude mice | i.p. | Spleen, liver (CM-dextran), Lungs (PEG-PEI) | Death at 2 mg/kg PEG-PEI FeONPs dosage | PEG-PEI in lung epithelial cells & interstitial spaces but not in macrophages | Sharma [ |
| FeONPs | PAMAM dendrimer | BALB/c | i.p. | kidney, liver, lungs > tumor | ↑ BUN, hyperglycemia, ↑LDH, ↑ Bilirubin | Edema & loss of cytoplasm in liver Apoptosis in cardiac tissue | Salimi [ |
| AuNPs | PBS stabilized (proprietary) | BALB/c | i.v. | liver, spleen > lung, kidney > brain, heart | Slight ↑ ALT, AST | Slight liver hemorrhage | Xia [ |
| AuNPs | Citrate | BALB/c | i.v. | Liver > spleen > lung > sternum > kidney > skin, heart, uterus, muscle, blood, brain | Discolored spleen, liver due to increased accumulation | Weaver [ | |
| AuNPs | Dextran | nude mice | i.v. | Liver > spleen ≫ tumor, lung, heart, brain | No apparent acute/chronic toxicity | Most NPs in Kupffer cells No hepatological changes or inflammation in kidney, spleen, heart | Bailly [ |
| AuNPs | Citrate | Wistar rats | i.p. | Spleen, liver, kidney, intestines | ↑ lipid peroxidation & carbonylation No changes in TNF-α, IL-1β, IL-6 and IL-10 | ↑ lipid droplets in hepatocytes | Lopez-Chaves [ |